Now #ESMO26: In a phase 2 trial evaluating an off-the-shelf peptide vaccine in patients with mKRAS PDAC, the 1ry endpoint of DFS was not met but prespecified analyses showed that s

Nature Medicine· @NatureMedicine · X·2026-10-23 19:06· 2 days agoScore90

Body

Now #ESMO26: In a phase 2 trial evaluating an off-the-shelf peptide vaccine in patients with mKRAS PDAC, the 1ry endpoint of DFS was not met but prespecified analyses showed that significant DFS was seen in the vaccine arm in patients with ctDNA- disease. dlvr.it/TW27M9

3150 views · 9 likes · 5 reposts · 0 replies

Conference abstracts

1017Pmatched by Developmental therapeutics

Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors

https://esmocongress.esmo.org

NCT06110663NCT06110663matched by - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

https://esmocongress.esmo.org

Source: Nature Medicine · x.com